Sustained Release Ashwagandha Supplement May Reduce Stress and Improve Sleep Quality: RCT

Why It Matters

The findings validate ashwaganda’s therapeutic claims, supporting premium pricing and product differentiation in a fast‑growing supplement segment. Demonstrated efficacy at a once‑daily low dose also improves consumer compliance, driving broader market adoption.

Key Takeaways

• 300 mg AshwaSR cut stress scores by 41.6% vs placebo
• 150 mg dose reduced stress by 38.6% and improved sleep
• High dose lowered cortisol levels, low dose showed no change
• Ashwagandha supplement market grew 13.8% in mainstream retail

Pulse Analysis

The randomized, double‑blind trial enrolled 135 adults with moderate stress, randomizing them to placebo, 150 mg or 300 mg of sustained‑release ashwagandha for two months. Results showed statistically significant reductions in perceived stress—38.6% for the low dose and 41.6% for the high dose—relative to placebo, with cortisol suppression observed only at 300 mg. Both groups reported better sleep quality, higher happiness scores, and healthier eating patterns, indicating that the herb’s adaptogenic properties extend beyond stress mitigation to broader well‑being metrics.

Ashwagandha’s market momentum underscores the commercial relevance of these findings. According to the American Botanical Council, U.S. sales of ashwagandha‑centric supplements approached $166 million, with a 13.8% year‑over‑year increase in mainstream channels. Consumer interest is driven by a blend of traditional Ayurvedic reputation and modern scientific validation, positioning the ingredient as a flagship adaptogen in the nutraceutical space. The sustained‑release formulation offers a differentiated product narrative, promising consistent plasma levels and once‑daily dosing—attributes that resonate with busy professionals seeking convenient stress‑relief solutions.

For manufacturers, the trial’s data provide a compelling evidence base to justify premium pricing and to pursue regulatory claims around stress reduction and sleep improvement. The demonstrated efficacy at 150 mg also opens opportunities for lower‑cost product lines, expanding accessibility without sacrificing performance. As the supplement industry faces heightened scrutiny over efficacy, such peer‑reviewed research can bolster brand credibility and support strategic partnerships with retailers focused on scientifically backed wellness solutions. Future studies may explore longer‑term outcomes, dosage optimization, and synergistic blends with other adaptogens, further cementing ashwagandha’s role in the next wave of evidence‑driven nutraceuticals.